NEW YORK, Jan. 24, 2022 /PRNewswire/ — The Suzhou Municipal Bureau of Culture, Radio, Television and Tourism is pleased to announce its headline sponsorship of IMM London which will take place 14-15 March 2022. Now in its tenth year, IMM is firmly established as the leading global event…
Comments Off on Suzhou Municipal Bureau of Culture, Radio, Television and Tourism Named Headline Sponsor of London’s International Media Marketplace
BRISBANE CITY, Australia, Jan. 24, 2022 /PRNewswire/ — Jungle Book Crypto, a committed cryptocurrency hub, is triumphantly back with its series of modern-day crypto-based products and brand-new presale of $JBC tokens. The platform has broadened the frontiers of the crypto jungle with the…
Comments Off on $JBC Tokens – An Admit Ticket to avail Multifarious Utilities, Splendid Perks, and Excellent Crypto Services
BOSTON, Jan. 24, 2022 /PRNewswire/ — NanoMosaic, the pioneer and leader in nanoneedle (MosaicNeedle™) technology detection for proteomics, genomics, and single-run experiment multi-omics applications has announced that it has signed a lease for a standalone building of 30,880 square feet…
Comments Off on NanoMosaic Signs 31K Square Foot Lease and Establishes “Multi-Omics World Headquarters” in Waltham, MA
NEW YORK, Jan. 24, 2022 /PRNewswire/ — Key takeaways: Nearly two-thirds of CEOs expect their organization’s growth to be “very strong” or “strong” over the next 12 months. Concerns about financial market instability and inflation have risen sharply with 36% of CEOs naming it as among the…
Comments Off on CEOs Eye 2022 With Optimism and a Dash of Uncertainty
SAN DIEGO, Jan. 24, 2022 /PRNewswire/ — Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that its Phase 1b clinical trial of VK0214 in…
Comments Off on Viking Therapeutics Announces Clinical Hold on Phase 1b Trial of VK0214 in Patients with X-ALD
INNSBRUCK, Austria, Jan. 24, 2022 /PRNewswire/ — The AV-Comparatives EPR test is the most comprehensive assessment of its kind in the world. Like all AV-Comparatives’ public test reports, the 2021 EPR Comparative Report is available for free:…
Comments Off on The independent ISO-certified security testing lab AV-Comparatives has released the results of its Endpoint Prevention and Response Test (EPR)
HAMILTON, Bermuda, Jan. 24, 2022 /PRNewswire/ — Nabors Industries Ltd. (“Nabors”) (NYSE: NBR) closed, on January 21, 2022, a secured $350 million revolving credit facility maturing on January 21, 2026. The new credit facility replaces the Company’s 2018 Revolving Credit Facility, which…
Comments Off on Nabors Announces New Revolving Credit Facility
BOSTON, Jan. 23, 2022 /PRNewswire/ — “It is important for parents in Massachusetts to explore and identify the best education options available to their children,” reads a proclamation just issued by Gov. Charlie Baker, recognizing this Jan. 23-29 as “Massachusetts School Choice Week.”…
Comments Off on Gov. Baker Celebrates Educational Opportunity, Proclaims Jan. 23-Jan. 29 “Massachusetts School Choice Week”
HANGZHOU and SHAOXING, China, Jan. 23, 2022 /PRNewswire/ — Ascletis Pharma Inc. (HKEX code: 1672) today announces the dosing of the first patient in the Phase III registration clinical trial of ASC40 combined with bevacizumab for treatment of recurrent glioblastoma (rGBM). ASC40 is an…
Comments Off on Ascletis Announces First Patient Dosed in the Phase III Clinical Trial of FASN Inhibitor ASC40 Combined with Bevacizumab for Treatment of Recurrent Glioblastoma
NETANYA, Israel, Jan. 23, 2022 /PRNewswire/ — Cellcom Israel Ltd. (TASE: CEL) announced today that an Extraordinary General Meeting of Shareholders (the “Meeting”) of Cellcom Israel Ltd. (the “Company”) will be held on Monday, February 28, 2022, at 16:00 p.m. (Israel time), at the…
Comments Off on CELLCOM ISRAEL LTD. ANNOUNCES EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS
« Previous Page —
Next Page »
